Warner Chilcott will discontinue manufacturing Duricef (cefadroxil monohydrate) 250mg/5mL and 500mg/5mL powder for oral suspension, effective March 1, 2008. Duricef is indicated for the treatment of susceptible urinary tract, skin and skin structure infections, pharyngitis/tonsillitis, and impetigo.

For more information call (800) 521-8813 or visit www.warnerchilcott.com.